nature.com search

Loading Filters

Showing 1–16 of 16 results

Loading Filters

Reviews | 16 December 2020
Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia
Leukemia , 1–4

Rights & permissionsfor article Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia . Opens in a new window.
Correspondence | 4 November 2019
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia
Bone Marrow Transplantation 55 , 669–672

Rights & permissionsfor article Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia . Opens in a new window.
Research | 12 November 2019
Need for routine examination of left ventricular ejection fraction in patients with AML
Leukemia 34 , 1169–1171

Rights & permissionsfor article Need for routine examination of left ventricular ejection fraction in patients with AML . Opens in a new window.
Editorial | 14 December 2018
Refining AML outcome prediction
Leukemia 33 , 283–284

Rights & permissionsfor article Refining AML outcome prediction . Opens in a new window.
News and Views | 23 May 2018
Next-generation sequencing for measuring minimal residual disease in AML
- Roland B. Walter
- & Frederick R. Appelbaum
Nature Reviews Clinical Oncology 15 , 473–474

Rights & permissionsfor article Next-generation sequencing for measuring minimal residual disease in AML . Opens in a new window.
Research | 18 February 2020
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia
- Colin D. Godwin
- , George S. Laszlo
- , Brent L. Wood
- , Colin E. Correnti
- , Olivia M. Bates
- , Eliotte E. Garling
- , Zhengwei J. Mao
- , Mary E. Beddoe
- , Margaret C. Lunn
- , Olivier Humbert
- , Hans-Peter Kiem
- & Roland B. Walter
Leukemia 34 , 2479–2483

Rights & permissionsfor article The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia . Opens in a new window.
Research | 23 January 2020
Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML
- Linde M. Morsink
- , Megan Othus
- , Evandro D. Bezerra
- , Brent L. Wood
- , Min Fang
- , Brenda M. Sandmaier
- , Marco Mielcarek
- , Gary Schoch
- , Rainer Storb
- , H. Joachim Deeg
- , Frederick R. Appelbaum
- & Roland B. Walter
Leukemia 34 , 1577–1587

Rights & permissionsfor article Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML . Opens in a new window.
Correspondence | 3 December 2019
Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease
- Linde M. Morsink
- , Evandro D. Bezerra
- , Megan Othus
- , Brent L. Wood
- , Min Fang
- , Brenda M. Sandmaier
- , Marco B. Mielcarek
- , H. Joachim Deeg
- , Gary Schoch
- , Frederick R. Appelbaum
- & Roland B. Walter
Leukemia 34 , 1701–1705

Rights & permissionsfor article Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease . Opens in a new window.
Editorial | 30 October 2019
Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
Bone Marrow Transplantation 55 , 843–850

Rights & permissionsfor article Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation . Opens in a new window.
Research | 4 October 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
Leukemia 34 , 635–639

Rights & permissionsfor article Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm . Opens in a new window.
Correspondence | 25 February 2019
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission
Bone Marrow Transplantation 54 , 1511–1514

Rights & permissionsfor article Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission . Opens in a new window.
Research | 5 October 2018
Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2
- Olivier Humbert
- , George S. Laszlo
- , Sophie Sichel
- , Christina Ironside
- , Kevin G. Haworth
- , Olivia M. Bates
- , Mary E. Beddoe
- , Ray R. Carrillo
- , Hans-Peter Kiem
- & Roland B. Walter
Leukemia 33 , 762–808

Rights & permissionsfor article Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of <i>CD33</i> exon 2 . Opens in a new window.
Research | 12 October 2018
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials
Leukemia 33 , 554–558

Rights & permissionsfor article Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials . Opens in a new window.
Research | 11 September 2018
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia
- Kristina Klupsch
- , Vanessa Baeriswyl
- , Roland Scholz
- , Joana Dannenberg
- , Roger Santimaria
- , David Senn
- , Elena Kage
- , Adrian Zumsteg
- , Isabella Attinger-Toller
- , Ulrike von der Bey
- , Susann König-Friedrich
- , Fanny Dupuy
- , Wibke Lembke
- , Clara Albani
- , Severin Wendelspiess
- , Lucijana Dinkel
- , Dorina Saro
- , Robert W. Hepler
- , George S. Laszlo
- , Chelsea J. Gudgeon
- , Julian Bertschinger
- , Simon Brack
- & Roland B. Walter
Leukemia 33 , 805–808

Rights & permissionsfor article COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia . Opens in a new window.
Research | 31 January 2018
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Leukemia 32 , 1239–1243

Rights & permissionsfor article Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation . Opens in a new window.
Research | 17 April 2018
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
- Anna B. Halpern
- , Megan Othus
- , Emily M. Huebner
- , Bart L. Scott
- , Pamela S. Becker
- , Mary-Elizabeth M. Percival
- , Paul C. Hendrie
- , Kelda M. Gardner
- , Tara L. Chen
- , Sarah A. Buckley
- , Kaysey F. Orlowski
- , Asma Anwar
- , Frederick R. Appelbaum
- , Harry P. Erba
- , Elihu H. Estey
- & Roland B. Walter
Leukemia 32 , 2352–2362

Rights & permissionsfor article Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms . Opens in a new window.

Refine your results by…

Filters

Filter By:

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia

Need for routine examination of left ventricular ejection fraction in patients with AML

Refining AML outcome prediction

Next-generation sequencing for measuring minimal residual disease in AML

The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia

Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML

Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease

Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Quick links

Refine your results by…

Filters ​

Filter By:

Search

Quick links

Filters